Welcome to our dedicated page for Sarepta Therapeutics, news (Ticker: SRPT), a resource for investors and traders seeking the latest updates and insights on Sarepta Therapeutics, stock.
Sarepta Therapeutics, Inc. develops and commercializes precision genetic medicines for rare diseases, with a central focus on Duchenne muscular dystrophy and other neuromuscular conditions. Company news commonly covers product revenue and commercialization trends for ELEVIDYS and PMO therapies, including AMONDYS 45, VYONDYS 53 and EXONDYS 51.
Updates also address FDA interactions for Duchenne therapies, clinical and biomarker data from the siRNA pipeline, and programs such as SRP-1001 for FSHD1 and SRP-1003 for DM1. Other recurring announcements include quarterly financial results, Nasdaq inducement equity grants, and patient-community initiatives tied to Duchenne muscular dystrophy.
Sarepta Therapeutics (NASDAQ:SRPT) has announced a significant refinancing of its convertible notes through privately negotiated exchange agreements. The company will exchange approximately $700 million of its 1.25% convertible senior notes due 2027 for new 4.875% convertible notes due 2030 worth $602 million, along with up to 6.7 million shares of common stock and $123.3 million in cash.
The new convertible notes have an initial conversion rate of 16.6667 shares per $1,000 principal amount, equivalent to a conversion price of approximately $60.00 per share, representing a 191.5% premium. Additionally, Sarepta entered into a private placement agreement with J. Wood Capital Advisors LLC for up to 1.4 million shares of common stock. The transactions are expected to close around August 28, 2025.
Sarepta Therapeutics (NASDAQ:SRPT) announced two significant financial transactions related to its siRNA collaboration with Arrowhead Pharmaceuticals. The company has sold 9,265,312 shares of Arrowhead stock in a block trade for $174 million in gross proceeds. Additionally, Sarepta will transfer 2,660,989 shares to Arrowhead to satisfy $50 million of a $100 million milestone payment.
The milestone payment was triggered by positive safety data review and achievement of enrollment targets in the Phase 1/2 study of SRP-1003, an RNAi therapeutic for type 1 myotonic dystrophy (DM1). Preliminary data from this study is expected in second half of 2025.
Sarepta Therapeutics (NASDAQ:SRPT) reported strong Q2 2025 financial results with total revenues of $611.1 million, up 68% year-over-year. The company achieved GAAP net income of $196.9 million and resumed ELEVIDYS shipments for ambulatory Duchenne patients following FDA review.
Key highlights include net product revenues of $513.1 million, a 42% increase year-over-year, and progress on their restructuring plan targeting over $100 million in cost savings through 2025. The company is advancing multiple siRNA programs with clinical readouts expected in 2025-2026 for FSHD, DM1, SCA2, and Huntington's Disease.
The strategic restructuring announced in July 2025 aims to reduce expenses by $400 million annually starting in 2026, positioning the company to repay its 2027 convertible notes while maintaining focus on high-impact programs.
Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, has announced it will release its second quarter 2025 financial results on Wednesday, August 6, 2025, after the Nasdaq market close. The company has noted that it will not host a conference call to discuss the results, as previously announced on July 16, 2025.
Sarepta maintains leadership positions in Duchenne muscular dystrophy treatments and is expanding its portfolio across muscle, central nervous system, and cardiac diseases.
Sarepta Therapeutics (NASDAQ:SRPT) announced that the FDA has recommended lifting the voluntary pause on ELEVIDYS shipments for ambulatory Duchenne muscular dystrophy patients. The FDA's swift review confirmed that a reported death of an 8-year-old patient in Brazil was unrelated to ELEVIDYS treatment.
The company will immediately resume shipping the gene therapy to treatment sites for ambulatory patients, while shipments for non-ambulatory patients remain paused pending further discussions with the FDA regarding risk-mitigation approaches. Sarepta will continue working with the FDA to complete safety label updates and determine the path forward for non-ambulatory patients.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has achieved a significant milestone in its collaboration with Sarepta Therapeutics (NASDAQ: SRPT), earning a $100 million payment. The milestone was triggered by reaching the first enrollment target in a Phase 1/2 clinical study of ARO-DM1, an RNAi therapeutic targeting type 1 myotonic dystrophy (DM1).
The company anticipates reaching a second enrollment target by the end of 2025, which would trigger an additional $200 million milestone payment. The current payment is expected to be received within 60 days, as per the license and collaboration agreement terms.
Sarepta Therapeutics (NASDAQ:SRPT) has issued a clarifying statement regarding a reported death of an eight-year-old Duchenne muscular dystrophy patient who received ELEVIDYS gene therapy. The company emphasized that the death was deemed unrelated to the treatment, as confirmed by both Roche Holding AG and the reporting physician.
The incident was reported to the FDA on June 18, 2025, through the FDA's postmarketing electronic database (FAERS). ELEVIDYS remains the only approved gene therapy for Duchenne muscular dystrophy, indicated for both ambulatory and non-ambulatory patients aged 4 years and above.
Sarepta Therapeutics (NASDAQ:SRPT) received a negative opinion from the European Medicines Agency's CHMP regarding the conditional marketing authorization for ELEVIDYS in treating Duchenne muscular dystrophy (DMD) patients aged 3-7 years in the EU.
While ELEVIDYS, the first gene therapy targeting DMD's underlying cause, has gained approval in the US and other countries since June 2023, Sarepta acknowledges current FDA safety inquiries. Despite not meeting the primary endpoint in the EMBARK study's first year, the therapy demonstrated statistically significant improvements in secondary endpoints. The company submitted additional efficacy data, including two-year EMBARK results and a three-year pooled analysis showing improvements in motor function.
Partner Roche will continue discussions with EMA to explore potential pathways for making ELEVIDYS available in the EU, while maintaining responsibility for regulatory approvals outside the US.
Sarepta Therapeutics (NASDAQ:SRPT) announced a voluntary and temporary pause of ELEVIDYS shipments in the United States, effective July 22, 2025. The pause will allow the company to address FDA information requests and complete the safety labeling supplement process for their Duchenne muscular dystrophy treatment.
ELEVIDYS is a single-dose gene therapy designed to treat Duchenne muscular dystrophy in patients aged 4 and older through the delivery of a transgene that codes for micro-dystrophin production in skeletal muscle. CEO Doug Ingram emphasized this was a difficult but necessary decision to maintain a productive relationship with the FDA.
Sarepta Therapeutics (NASDAQ:SRPT) responded to an informal FDA request to voluntarily halt shipments of ELEVIDYS, their approved gene therapy for Duchenne muscular dystrophy. The company will continue shipping to ambulant patients while pausing shipments for non-ambulant patients pending label updates and enhanced immunosuppression protocols.
The statement addresses a recent death of a 51-year-old non-ambulant LGMD patient in a Phase 1 trial, clarifying this was related to a different investigational therapy (SRP-9004) for Limb-Girdle Muscular Dystrophy, not ELEVIDYS. The company reported the acute liver failure event to FDA on June 20, 2025, with follow-up notification of death on July 3, 2025.